Clinical trial
Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe…
NCT00482508 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00482508 |
|---|---|
| Title | Safety and Tolerability of Omalizumab in Poorly Controlled Moderate to Severe Asthma Patients |
| Official title | A One Year Open-label Extension Study to Assess Long Term Safety and Tolerability of Omalizumab Treatment in Poorly Controlled Moderate to Severe Allergic Asthma Patients Who Participated in the 52-week CIGE24IA04E1 Study |
| Lead sponsor | Novartis, Industry |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | Omalizumab |
| Enrollment | 95 |
| Start date | May 1, 2003 |
| Primary completion | Oct 1, 2005 |
| Completion | Oct 1, 2005 |
| First posted | Jun 5, 2007 |
| Last update posted | Oct 25, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: